Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive

Reape, Kathleen Z.; DiLiberti, Charles E.; Hendy, Christopher H.; Volpe, Edward J.

doi:10.1016/j.contraception.2007.09.010

Cited by 31 publications

(25 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The current study findings are consistent with previous studies showing that the addition of low-dose EE during the traditional HFI results in a delay in the rise of estradiol and provides effective suppression of ovarian follicular activity [8,13,14]. In the current study, similar patterns of hormonal suppression, including E2, P, FSH and LH, were shown in the subjects who received the 21/7-active COC regimen with only low-dose EE during the traditional HFI and the subjects who received extended COC in the 24/4 DRSP/EE+4 days PBO regimen.…”

Section: Discussionsupporting

confidence: 95%

“…Shortening the HFI may increase the efficacy of low-estrogen-dose contraceptive regimens [4,8,11,12]. Alternatively, the addition of low-dose estrogen during the usual 7-day HFI has produced greater ovarian suppression, less risk of escape ovulation and improvements in hormonerelated symptoms and breakthrough bleeding, and has been shown to be safe and efficacious [8,13,14].…”

Section: Introductionmentioning

confidence: 96%

See 1 more Smart Citation

Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial

Seidman

Kroll²,

Howard³

et al. 2015

Contraception

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 95%

Section: Introductionmentioning

confidence: 96%

Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial

Seidman

Kroll²,

Howard³

et al. 2015

Contraception

View full text Add to dashboard Cite

“…Supplementation of estrogen during the HFI is another option,79 with the addition of low-dose estrogen in place of placebo improving the bleeding pattern in subsequent cycles 80 81…”

Section: Resultsmentioning

confidence: 99%

Evolution of extended use of the combined oral contraceptive pill

Panicker

Mann

Shawe

et al. 2014

J Fam Plann Reprod Health Care

View full text Add to dashboard Cite

Background Extended use of the combined oral contraceptive pill (COC), defined as taking active pills for at least 28 days, has been used in order to avoid bleeding at important times and to treat gynaecological conditions such as endometriosis. We examined the main issues involved in extended use of the COC and how it has evolved from being one of medicine's best-kept secrets to becoming more widely accepted by women and the medical community. Study design Literature review, using Medline, Embase, Pubmed, CINHAL Plus, the Cochrane Database of Systematic Reviews and the Ovid database for all relevant clinical trials, systematic reviews, meta-analyses, literature reviews, scientific papers and individual opinions between 1950 and October 2013. Results Accumulating evidence supports various forms of extended pill use as suitable alternatives to the standard (21/7) regimen. In terms of user preference, much hinges on whether women wish to reduce the frequency or duration of scheduled bleeding on the combined pill. Available data on the safety of extended pill regimens do not give cause for concern, but longer term data should be collected. Conclusions Information for women considering extended COC regimens should keep pace with research findings to ensure that women and clinicians are better informed about the choices available.

show abstract

“…The use of low-dose ethinylestradiol 10 lg during the usual 7-day hormone-free interval resulted in greater suppression of the hypothalamic-pituitary-ovarian axis and decreased follicular development in women than OC regimens using placebo [11,12]. A randomized, openlabel trial (n = 33) compared three OC regimens containing levonorgestrel/ethinylestradiol 150/30 lg: three cycles of a standard 21/7-day regimen with 7 days of placebo (21/7 placebo), an extended 84-day regimen with 7 days of placebo (84/7 placebo) and Seasonique Ò [12].…”

Section: Contraceptive Effectsmentioning

confidence: 96%

Extended-Cycle Levonorgestrel/Ethinylestradiol and Low-Dose Ethinylestradiol (Seasonique®): A Review of Its Use as an Oral Contraceptive

Burness

2015

Drugs

View full text Add to dashboard Cite

A 91-day extended-cycle oral contraceptive (OC) consisting of levonorgestrel/ethinylestradiol 150/30 µg for 84 days and ethinylestradiol 10 µg for 7 days (Seasonique(®)) has recently been approved for the prevention of pregnancy in adult women in the EU. This regimen allows for a reduction in the number of withdrawal bleeding episodes to four per year, compared with 13 episodes per year with conventional 28-day regimens. Seasonique(®) was effective in preventing pregnancy in a large (n = 1006), noncomparative trial of healthy, sexually active women. In this trial, the overall Pearl index (pregnancies per 100 woman-years of use) in women aged 18-35 years (n = 621) was 0.76 and the Pearl index for method-failure (compliant use) was 0.26. Scheduled (withdrawal) bleeding and/or spotting remained fairly constant over time, with a mean of 2 days of bleeding and 1 day of spotting per each 91-day cycle. Unscheduled bleeding and unscheduled spotting was highest during the first few cycles of use and decreased thereafter. Seasonique(®) was generally well tolerated, with a tolerability profile in line with that expected for OCs. Seasonique(®) extends the contraceptive options currently available to women, particularly in those who desire fewer withdrawal bleeding episodes.

show abstract

Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive

Cited by 31 publications

References 16 publications

Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial

Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial

Evolution of extended use of the combined oral contraceptive pill

Extended-Cycle Levonorgestrel/Ethinylestradiol and Low-Dose Ethinylestradiol (Seasonique®): A Review of Its Use as an Oral Contraceptive

Contact Info

Product

Resources

About